Cyteir Therapeutics

c/o Lab Central
700 Main Street
Cambridge
Massachusetts
02139
United States

Show jobs for this employer

2 articles about Cyteir Therapeutics

Push to Public Continues as Biotech Dominates the IPO List This Week

6/17/2021

Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors

3/31/2019

Novel, targeted, oral drug candidate inhibits DNA-repair protein to induce cell death in multiple cancer types including pancreatic cancer and B-cell non-Hodgkin lymphoma